However, the clinical response rate to anti-PD-1/PD-L1 antibodies is still 10–40% in different advanced cancers [95,96], restricting their usefulness in cancer therapy [97] and suggesting the existence of different immunosuppressive mechanisms in cancer-bearing hosts. This evidence concerns the gene CD274 and cancer.